GlaxoSmithKline plc Receives Buy Rating from Shore Capital Stockbrokers (GSK)
GlaxoSmithKline plc (LON:GSK)‘s stock had its “buy” rating restated by stock analysts at Shore Capital Stockbrokers in a report issued on Monday, American Banking News.com reports.
Shares of GlaxoSmithKline plc (LON:GSK) opened at 1667.4999 on Monday. GlaxoSmithKline plc has a one year low of GBX 1528.00 and a one year high of GBX 1816.00. The stock’s 50-day moving average is GBX 1608. and its 200-day moving average is GBX 1613.. The company’s market cap is £79.893 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at UBS AG reiterated a “neutral” rating on shares of GlaxoSmithKline plc in a research note on Wednesday, April 23rd. They now have a GBX 1,500 ($25.20) price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline plc in a research note on Wednesday, April 23rd. Finally, analysts at Deutsche Bank raised their price target on shares of GlaxoSmithKline plc from GBX 1,620 ($27.22) to GBX 1,750 ($29.40) in a research note on Wednesday, April 23rd. They now have a “hold” rating on the stock. Four equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of GBX 1,714.78 ($28.81).
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.